>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal sequence Analysis
Predicted Molecular Mass
36-44 kDa, under reducing conditions
Measured by its binding ability in a functional ELISA. When Recombinant Mouse BTNL4 Fc Chimera (Catalog # 9590-BT) is immobilized at 2 µg/mL (100 µL/well), Recombinant Mouse LSECtin/CLEC4G (Catalog # 10363-CL) binds with an ED50 of 0.15-1.2 μg/mL.
Scientific Data Examples for Recombinant Mouse LSECtin/CLEC4G Protein, CF
Recombinant Mouse LSECtin/CLEC4G Protein Binding Activity
When Recombinant Mouse BTNL4 Fc Chimera (Catalog # 9590-BT) is immobilized at 2 µg/mL (100 µg/well), Recombinant Mouse LSECtin/CLEC4G (Catalog # 10363-CL) binds with an ED50 of 0.15-1.2 µg/mL.
Recombinant Mouse LSECtin/CLEC4G Protein SDS-PAGE
2 μg/lane of Recombinant Mouse LSECtin/CLEC4G (Catalog # 10363-CL) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 36-44 kDa and 110-130 kDa, repsectively.
Formulation, Preparation and Storage
What does CF mean?
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our
Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant
protein to be stored at a more dilute concentration.
The carrier free version does not contain BSA.
What formulation is right for me?
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or
as an ELISA standard.
In contrast, the carrier free protein is recommended for applications, in which the presence of BSA
Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitute at 500 μg/mL in PBS.
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
3 months, -20 to -70 °C under sterile conditions after reconstitution.
LSECtin (liver and lymph node sinusoidal endothelial cell C-type lectin), also known as C-type lectin superfamily 4 member G (CLEC4G), is a member of subgroup II of the C-type (Ca2+-dependent) lectin superfamily (1). The protein was named LSECtin because its initial expression was described to be restricted to liver and lymph node sinusoidal endothelial cells (1). However, LSECtin has also been detected in peripheral blood and thymic dendritic cells isolated ex vivo, and in monocyte-derived macrophages and dendritic cells at the RNA and protein level (2). Mouse LSECtin is a type II transmembrane glycoprotein that includes an N-terminal cytoplasmic tail (aa 1-30), a 21 aa transmembrane region, and a 243 aa extracellular domain (ECD). Within the ECD, mouse LSECtin shares 66% and 85% aa sequence identity with human and rat LSECtin, respectively. LSECtin binds to mannose, GlcNAc, and fucose in a Ca2+-dependent manner (1-3). In addition, LSECtin has the ability to bind to surface glycoproteins of enveloped viruses (3, 4). In particular, interaction of LSECtin with the surface glycoproteins of severe acute respiratory syndrome (SARS) coronavirus and Ebola virus has been described, and LSECtin-mediated infection of cells by Ebola virus has been demonstrated (3, 4). LSECtin is highly expressed on tumor-associated macrophages (TAMs) and enhances stemness of breast cancer cells (BCCs) (9). We identified BTN3A3, a B7 family member with previously unknown functions as the receptor for LSECtin on BCCs responsible for stemness-promoting effect of LSECtin (9). In mice bearing human tumor xenografts, either macrophage-specific ablation of LSECtin or silencing of BTN3A3 in BCCs decreased CSC frequency and tumor growth (9). Administration of LSECtin-positive macrophages increased the tumorigenic activity of BCCs dependent on BTN3A3 (9). Disruption of the LSECtin-BTN3A3 axis with BTN3A3-Fc or anti-BTN3A3 mAb has a therapeutic effect on breast cancer (9). These findings define a juxtacrine signaling mechanism by which TAMs promote cancer stemness (9). Targeting this axis in the CSC niche may provide potential therapies to breast cancer (9).
Liu, W. et al. (2004) J. Biol. Chem. 279:18748.
Dominguez-Soto, A. et al. (2007) Blood 109:5337.
Powlesland, A. et al. (2008) J. Biol. Chem. 283:593.
Gramberg, T. et al. (2005) Virology 340:224.
Yamashiro, H. et al. (2010) J. Leukoc Biol. 88:757.
Compte, E. et al. (2004) Eur. J. Immunol. 34:2089.
Abeler-Dorner, L. et al. (2012) Trends Immunol. 33:34.
Bas, A. et al. (2011) Proc Natl Acad Sci U S A. 108:4376.
Liu, D. et al. (2019) Cell Res. 29:5.
Liver And Lymph Node Sinusoidal Endothelial Cell C-type Lectin
Entrez Gene IDs
339390 (Human); 75863 (Mouse)
C-type lectin domain family 4 member G, C-type lectin domain family 4, member G, C-type lectin superfamily 4, member G, CLEC4G, DTTR431, LP2698, LSECtin, Q6UXB4, UNQ431, liver and lymph node sinusoidal endothelial cell C-type lectin
Citations for Recombinant Mouse LSECtin/CLEC4G Protein, CF
Please visit our Instrument Citation Database to search our collection of scientific articles that feature our instruments.
Product Documents for Recombinant Mouse LSECtin/CLEC4G Protein, CF
Which Brands are Currently Available on bio‑techne.com? R&D Systems, Tocris Bioscience and ProteinSimple branded products are available to purchase through bio‑techne.com. ProteinSimple branded instruments are available to quote. ACD branded products will be available on bio‑techne.com in the near future. Novus Biologicals branded products are not currently available on bio‑techne.com and can be found at novusbio.com.
Setting the standard in quality research reagents for over 30 years
A trusted leader in quality life science reagents
Your trusted supplier for innovative and high performance life science reagents
Proprietary systems and consumables for simpler, more quantitative and affordable protein analysis
Proprietary RNAscope® technology capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity
A world leader in developing liquid biopsy based diagnostics